These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11772421)

  • 21. [Atherosclerosis in light of the evidence from large statin trials].
    Cortese C; Bernardini S; Motti C
    Ann Ital Med Int; 2000; 15(1):103-7. PubMed ID: 10842899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory effects of HMG-CoA reductase inhibitors.
    Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
    Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The promise of statins].
    Capurso A
    Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins in sepsis.
    Dobesh PP; Swahn SM; Peterson EJ; Olsen KM
    J Pharm Pract; 2010 Feb; 23(1):38-49. PubMed ID: 21507792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)].
    Igel M; Sudhop T; von Bergmann K
    Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of statins on novel risk markers.
    Cignarella A; Bolego C; Paoletti R
    Cardiovasc Drugs Ther; 2003 Jul; 17(4):361-6. PubMed ID: 14696629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid lowering therapy in atherosclerosis.
    Aikawa M; Libby P
    Semin Vasc Med; 2004 Nov; 4(4):357-66. PubMed ID: 15861316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins in atherothrombosis.
    Colli S; Werba JP; Tremoli E
    Semin Vasc Med; 2004 Nov; 4(4):407-15. PubMed ID: 15861322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers.
    Kuvin JT; Karas RH
    Curr Opin Cardiol; 2003 Jul; 18(4):295-300. PubMed ID: 12858128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis.
    Deng J; Wu Q; Liao Y; Huo D; Yang Z
    Nephrology (Carlton); 2012 Aug; 17(6):545-51. PubMed ID: 22429568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
    Koh KK
    Cardiovasc Res; 2000 Sep; 47(4):648-57. PubMed ID: 10974215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammation and the development of atherosclerosis.
    Mizuno Y; Jacob RF; Mason RP
    J Atheroscler Thromb; 2011; 18(5):351-8. PubMed ID: 21427505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin therapy-evidence beyond lipid lowering contributing to plaque stability.
    de Lorenzo F; Feher M; Martin J; Collot-Teixeira S; Dotsenko O; McGregor JL
    Curr Med Chem; 2006; 13(28):3385-93. PubMed ID: 17168712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.
    Diamantis E; Kyriakos G; Quiles-Sanchez LV; Farmaki P; Troupis T
    Curr Cardiol Rev; 2017; 13(3):209-216. PubMed ID: 28462692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease].
    Galle J
    Herz; 2004 Feb; 29(1):4-11. PubMed ID: 14968336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.